ECTRIMS 2018: Day 3 Update

Written by Sharon Salt, Editor

Video highlight You might also like: ECTRIMS 2018: Day 1 Update ECTRIMS 2018: Day 2 Update Landmark simvastatin trial for secondary progressive multiple sclerosis begins in the UK Ibudilast decreases progression of brain atrophy in progressive multiple sclerosis Today’s feature Ask the Experts: Emerging therapies in multiple sclerosis (Part I: mechanisms, therapies and challenges) Pick of the posters Kapoor R, Sellebjerg F, Hartung H-P et al. Natalizumab reduced serum levels of neurofilament light chain in secondary progressive multiple sclerosis patients from the Phase III ASCEND study. This study evaluated the associations of serum neurofilament light chain (sNfL) and disease activity, disability progression...

To view the full article, please register now for access

It's completely free